Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations
- 1 April 1994
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (4) , 773-780
- https://doi.org/10.1128/aac.38.4.773
Abstract
The emergence of multidrug-resistant strains of Mycobacterium tuberculosis has resulted in increased interest in the fluoroquinolones (FQs) as antituberculosis agents. To investigate the frequency and mechanisms of FQ resistance in M. tuberculosis, we cloned and sequenced the wild-type gyrA and gyrB genes, which encode the A and B subunits of the DNA gyrase, respectively; DNA gyrase is the main target of the FQs. On the basis of the sequence information, we performed DNA amplification for sequencing and single-strand conformation polymorphism analysis to examine the presumed quinolone resistance regions of gyrA and gyrB from reference strains (n = 4) and clinical isolates (n = 55). Mutations in codons of gyrA analogous to those described in other FQ-resistant bacteria were identified in all isolates (n = 14) for which the ciprofloxacin MIC was > 2 micrograms/ml. In addition, we selected ciprofloxacin-resistant mutants of Mycobacterium bovis BCG and M. tuberculosis Erdman and H37ra. Spontaneously resistant mutants developed at a frequency of 1 in 10(7) to 10(8) at ciprofloxacin concentrations of 2 micrograms/ml, but no primary resistant colonies were selected at higher ciprofloxacin concentrations. Replating of those first-step mutants selected for mutants with high levels of resistance which harbored gyrA mutations similar to those found among clinical FQ-resistant isolates. The gyrA and gyrB sequence information will facilitate analysis of the mechanisms of resistance to drugs which target the gyrase and the implementation of rapid strategies for the estimation of FQ susceptibility in clinical M. tuberculosis isolates. ImagesThis publication has 34 references indexed in Scilit:
- Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1993
- Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coliAntimicrobial Agents and Chemotherapy, 1993
- Detection of rifampicin-resistance mutations in Mycobacterium tuberculosisThe Lancet, 1993
- Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencingAntimicrobial Agents and Chemotherapy, 1992
- New topoisomerase essential for chromosome segregation in E. coliCell, 1990
- Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coliAntimicrobial Agents and Chemotherapy, 1990
- Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapyAntimicrobial Agents and Chemotherapy, 1990
- Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12Antimicrobial Agents and Chemotherapy, 1986
- DNA TOPOISOMERASESAnnual Review of Biochemistry, 1985
- Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populationsAntimicrobial Agents and Chemotherapy, 1984